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Summary
Objective: Cathepsin K (cat K), a cysteine protease expressed in osteoclasts, chondrocytes and synovial ﬁbroblasts, degrades several bone
and cartilage matrix components suggesting its potential role in osteoarthritis (OA). We investigated the effects of SB-553484, an inhibitor of
cat K, on lesion severity and biomarkers of collagen degradation in the canine partial medial meniscectomy model.
Methods: A partial medial meniscectomy was performed in mature female beagle dogs. Animals were dosed orally with vehicle or SB-553484
at 50 mg/kg BID for 28 days. The femorotibial joints were evaluated for gross and microscopic histological changes. Biomarkers of collagen
degradation were also analyzed.
Results: In dogs treated with SB-553484, subjective gross and calculated degeneration scores decreased signiﬁcantly by 29% and 46%, re-
spectively. Histopathologic evaluation demonstrated that the summed tibial degeneration score decreased signiﬁcantly by 21%. Inhibition of
tibial cartilage degeneration was signiﬁcant in zone 1 (32%) and the depth ratio of any tibial matrix change was decreased signiﬁcantly by
28%. Urinary biomarkers of bone and cartilage degradation were also signiﬁcantly reduced.
Conclusion: Treatment with SB-553484 resulted in mild to moderate beneﬁcial effects on gross and histopathological parameters. Reduction
of biomarkers of collagen type I and II degradation indicated a direct effect of the compound on bone and cartilage. These data suggest that
the prevention of cartilage degradation by cat K inhibition may represent a valid strategy for pharmacological intervention in OA and that mon-
itoring collagen degradation biomarkers may provide an indication of the protective effects of inhibition of bone and cartilage degradation.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a chronic degenerative joint disease
characterized by progressive loss of articular cartilage ac-
companied by pain and loss of function in affected joints.
OA is the most common type of arthritis and it is a major
cause of disability estimated to affect approximately 15%
of the US population1,2. OA is associated with aging and
nearly 80% of individuals over 65 years of age are believed
to have OA3. Current treatments are palliative and provide
only symptomatic relief with eventual total joint replacement
as the ﬁnal option. There are no disease-modifying pharma-
ceutical agents approved for the treatment of OA. As such
there is a tremendous need to identify molecular targets
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1236potential to address the underlying structural damage oc-
curring in OA.
Pathological changes in OA include the progressive de-
struction of articular cartilage matrix including proteoglycan
and collagen type II degradation, subchondral bone
changes and osteophyte formation culminating in the loss
of articular cartilage4.
Cathepsin K (cat K), a cysteine protease, was identiﬁed
initially in osteoclasts5 and subsequently demonstrated to
be expressed at levels higher than cathepsins B, L or S in
human osteoclasts6. Cat K can degrade several bone ma-
trix proteins including type I collagen (CTX-I) during osteo-
clastic bone resorption7. It has been proposed that
subchondral bone remodeling may play an important role
in the pathogenesis of OA. Recent studies have shown a re-
lationship between increased subchondral bone changes
and the early stages of OA in animal models8. In addition,
the expression of cat K has also been reported in human ar-
thritic synovium9e11 and cartilage12,13. Furthermore, in
transgenic mice, the overexpression of cat K results in the
spontaneous development of synovitis and cartilage degra-
dation14. Consistent with these observations, cat K cleaves
type II collagen (CTX-II)15,16 and aggrecan17. Finally, sev-
eral anti-resorptive agents including alendronate have
been shown to have a chondroprotective activity in animal
1237Osteoarthritis and Cartilage Vol. 17, No. 9models of OA18. Therefore, cat K may play an important di-
rect role in the cartilage degradation characteristic of OA
pathology in addition to its role in bone and synovium.
These observations prompted us to evaluate a cat K inhib-
itor in a dog model of experimental OA.
Here we report the protective effects of SB-553484, an
orally available inhibitor of dog cat K, on cartilage lesion se-
verity in a prophylactic study of partial medial meniscec-
tomy-induced OA in the dog. The analyses of biomarkers
of bone and cartilage turnover are also reported.Materials and methodsREAGENTSSB-553484 was prepared at GlaxoSmithKline Pharmaceuticals, College-
ville, PA. Hydroxypropylmethylcellulose, Sigma, St. Louis, MO.IN VITRO POTENCY OF SB-553484 ON CANINE CATHEPSINS
AND IN VIVO PHARMACOKINETICSInhibition of dog cat K activity was measured as previously described us-
ing the Z-Phe-Arg-AMC substrate19. Inhibition of dog cathepsins B and L was
measured under identical conditions using the same substrate. Dog cathep-
sin S activity was measured using the substrate Ac-Lys-Gln-Lys-Leu-Arg-
AMC in 50 mM MES (4-Morpholineethanesulfonic acid), 5.0 mM EDTA,
10 mM cysteine pH 6.5 in 2% dimethyl sulfoxide. As appropriate, linear por-
tions of the initial velocity data from product progress curves were analyzed
to generate steady-state kinetic constants. A standard curve with 7-amino-4-
methyl coumarin was used in the conversion of ﬂuorescence to molar units.
To determine drug levels in plasma, SB-553484 was extracted by protein
precipitation using acetonitrile containing [15N13C3]-SB-553484 as an internal
standard. Extracts were analyzed by HPLC-MS/MS using a TurboIonSpray
interface and multiple reaction monitoring.SURGICAL MODEL AND TREATMENTSOA was induced in 40 adult (14e15 month old) female beagle dogs in the
left femorotibial joint by surgical transection of the medial meniscus. Prior to
surgery, dogs were medicated with glycopyrrolate (0.005 mg/kg), morphine
(1 mg/kg) and acepromazine (0.05 mg/kg) injected intramuscularly. Each
dog was anesthetized with Isoﬂurane in oxygen delivered through a face
mask until anesthetized deeply enough for endotracheal intubation. The me-
dial aspect of the left femorotibial joint was clipped of hair and prepared for
surgery by alternating scrubs using gauze soaked in chlorhexidine surgical
scrub and sterile saline. The femorotibial joint was given a ﬁnal chlorhexi-
dine/saline scrub and then draped with a sterile, disposable fenestrated
drape and a skin incision was made over the medial aspect of the femoroti-
bial joint and the medial collateral ligament was exposed by blunt dissection.
The medial meniscus was reﬂected medially with a hemostat and a cut was
made through the full thickness and approximately 1/3 to 1/2 of it was re-
moved. The synovium and skin were closed with 3.0 Vicryl suture. Animals
were given an analgesic post-surgically including a 2.5 mg fentanyl skin
patch applied just before surgery (effective for up to 72 h post-surgery) fol-
lowed by morphine (1 mg/kg, sc) for the ﬁrst 12 hours post-surgery. Surger-
ies were performed at Bolder BioPATH Incorporated (Boulder, CO).
The dogs were randomized into two groups of 20 which received twice daily
oro-gastric gavage administrations of vehicle (1.5% hydroxypropylmethylcel-
lulose) or SB-553484 at 50 mg/kg (10 mg/ml suspension in vehicle) beginning
1 day prior to surgery and continuing through day 28. Animals were housed to-
gether in groups with space for social enrichment and exercise. Animals were
evaluated subjectively once per day for mobility and activity and body weights
were recorded weekly. Urine samples were collected at pre-study and days 7,
14 and 21 during the study. On day 28, dogs were euthanized by intravenous
injection of a pentobarbital-based euthanasia solution (pentobarbital dose
88 mg/kg) and the left femorotibial joints were removed and processed for his-
tological analysis. All procedureswere performed in accordancewith protocols
approved by the Institutional Animal Care and Use Committee for compliance
with laws and regulations in the USA.GROSS MACROSCOPIC SCORING OF JOINTSAt the termination of the study, the left femorotibial joint was opened, and
disarticulated. The observers were blinded regarding the treatment. Joints
were examined for evidence of infection and for the meniscal damage result-
ing from surgery. The gross cartilage lesions were measured (lengthwidth
at the widest points using a centimeter ruler) and depth was described as su-
perﬁcial, moderate, or deep.The lesions on themedial tibiawere scored, as follows. Gross subjective car-
tilage degeneration scoreswere assigned, as follows. The area (lengthwidth;
mm2) measures were used to generate an assigned subjective gross score,
where: 0¼ normal; 1¼ superﬁcial degeneration area up to 10 mm2;
2¼ superﬁcial degeneration area greater than 10 mm2; 3¼moderate degener-
ation area up to 15 mm2; 4¼moderate degeneration area greater than 15 mm2.
Subjective gross scores for the lesions were summed to generate an overall in-
dex of subjective cartilage degeneration for the medial tibial plateau. Gross cal-
culated scores were derived for the central regions by calculating the actual
measured length actual measured width the depth score (with depth score
of 1¼ superﬁcial, 2¼medium and 3¼ deep, based on the gross description).
The gross calculated scores were summed to achieve a total calculated gross
score for the medial tibial plateau. The mean standard error (SE) for each of
these parameters in the medial tibial compartment was determined for compar-
ative purposes.MICROSCOPIC HISTOLOGICAL SCORING OF JOINTSAtnecropsy, thedisarticulated left femorotibial jointsweresawed into six fron-
tal slabs of approximately equal size and placed in cassettes with the anterior
surface down. The slabs were designated anterior, middle and posterior
(Fig. 1). The tissueswere ﬁxed in 10%neutral buffered formalin for 48 h followed
bydecalciﬁcation in Immunocal. Followingparafﬁn embedding, the tissueswere
sectioned (8 mm) and stained with Toluidine blue for microscopic evaluation.
Histopathologic evaluation of the cartilage damage was completed as fol-
lows20. Measurements of width of total lesion of any type (including chondro-
cyte death, cloning, ﬁbrillation, proteoglycan loss) were taken across the
medial tibial surface togive a total lesionwidth (Fig. 1).Multiple depthmeasure-
ments in areas of greatest lesion severity were taken for each of the four quad-
rants in each of the three anterior to posterior sections. These measures were
taken from the surface to the point where cartilage appeared normal (Fig. 1). A
second measure was taken in the same area to the depth of the tidemark; the
number was expressed as a ratio of lesion depth vs depth of tidemark (Fig. 1).
The mean values for each quadrant (medial to lateral) for the three anterior to
posterior sections were determined as well as overall mean for the joint.BIOMARKER ANALYSISFor 24 hurine samples, dogswere placed inmetabolism cages and the total
urine volume was collected and recorded. Urine was collected at pre-surgery
days 15 and 8 and post-surgery days 7 and 21. Samples for analysis
were centrifuged and supernatant aliquots were frozen at 70C until time of
assay. Urinary collagen type I and II degradation products (c-terminal cross-
linking telopeptide of CTX-I and CTX-II, respectively) were measured using
the Nordic Bioscience (Herlev, Denmark) CTX-I and CTX-II ELISA according
to the manufacturer’s recommendations. The Interassay CVs (Coefﬁcient of
variability) for the CTX-I and CTX-II were 5.7% and 8.1%, respectively.
The assays measure degradation products of collagen in non-human urine.
CTX-I and CTX-II values were corrected for creatinine concentration. Urine
samples were assayed for creatinine concentration on the Olympus AU640
Chemistry Immuno Analyzer.STATISTICAL ANALYSISMeansSEs for the histological parameters and biomarker analyses
were calculated and groups were compared using the Student’s t test with
signiﬁcance set at P 0.05.ResultsCOMPOUND CHARACTERISTICSSB-553484, an azepanone class pan cathepsin inhibitor21,
is an orally bioavailable small molecule inhibitor of both hu-
man and dog cat K. In pharmacokinetic studies, the oral bio-
availability was determined to bew36%. SB-553484 is most
potent against cat K (IC50¼ 0.055 nM) in the dog and much
less potent on other cathepsins exhibitingw14.9e3000-fold
selectivity for cathepsins L, S and B (Table I).THE CANINE PARTIAL MEDIAL MENISCECTOMY MODEL OF OAFollowing partial medial meniscectomy and during the
course of the study, animals were housed together in
groups with space for exercise. The daily activity levels of
the vehicle and compound treated animals were
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Fig. 1. Compartmentalization of the medial tibial plateau for histological scoring. The anterior to posterior orientation of levels 1, 2 and 3 and
the medial to lateral orientation of zones 1, 2, 3, and 4 are designated in the illustration (Fig. 1a). Zones 1e4 are indicated by number, with
zone 4 continuing to the cartilage edge (not shown; as indicated by the black arrow) (Fig. 1b). The total degeneration width (black bar) vs the
substantive degeneration width (green bar) is demonstrated across zones 1e4 (Fig. 1b, left) where substantive degeneration was deﬁned as
chondrocyte and proteoglycan loss with ﬁbrillation extending into the upper middle zone or deeper. The total matrix depth (red bar) vs the
substantive damage matrix depth (yellow bar) is illustrated (Fig. 1b, right).
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1238 J. R. Connor et al.: Cathepsin K inhibition protective in OAcomparable and there was no signiﬁcant weight change in
any of the animals. There was no evidence of joint infection
in any of the animals and the meniscal damage resulting
from surgery was similar in both vehicle and compound
treated groups. Gross and histopathological evaluation of
the left femorotibial joint at 4 weeks following partial medial
meniscectomy revealed typical articular cartilage degenera-
tive changes with focal, well circumscribed lesions primarily
on the medial tibias. Since lesions on the femoral condyles
of vehicle treated animals were minimal, we have only pre-
sented the data obtained for the medial tibia. Osteophytes
were not apparent in any of the animals.4.0
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for lesion development and severity. Treatment with the cat K
inhibitor, SB-553484, signiﬁcantly reduced the mean medialTable I
In vitro potency of SB-553484 on canine cathepsins. SB-553484 is
an azepanone with high potency against dog cat K (0.055 nM
IC50). It is active against cats S, L and B at lower potencies
Cathepsins IC50 (nM) Fold selectivity for cat K
K 0.055 e
S 3.7 67.2
L 0.82 14.9
B 160 2909tibial plateausubjectivegrossscoreby29%vsvehiclecontrols
(Fig. 2). Themeanmedial tibial plateau calculated gross score
was reduced signiﬁcantly by 46% in the SB-553484-treated
group compared to that of vehicle controls (Fig. 2).MICROSCOPIC TIBIAL CARTILAGE DEGENERATION SCORES
WERE REDUCED SIGNIFICANTLY BY INHIBITION OF CAT KTreatment with SB-553484 signiﬁcantly reduced the le-
sion score for cartilage degeneration for all three levels0.0
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Fig. 2. Medial tibia gross subjective and calculated morphology
scores. Treatment with SB-553484 reduced signiﬁcantly the
mean medial tibial plateau subjective gross score by 29%
(*P 0.05) and the mean medial tibial plateau calculated gross
score by 46% (*P 0.05) vs vehicle controls. n¼ 20 per group.
1239Osteoarthritis and Cartilage Vol. 17, No. 9combined (Sum) as well as the middle level weight bearing
compartment of the tibia by 21% and 16%, respectively,
compared to vehicle controls (Fig. 3a).
In a similarmanner, articular cartilage degenerationwas as-
sessedmicroscopically in theoutside,middleand insidezones
of the tibial plateau. Treatment with SB-553484 reduced the
sum of tibial cartilage degeneration scores for all zones com-
bined by 21% vs vehicle controls. The treatment protection
was statistically signiﬁcant for zone 1 (32%) (Fig. 3b).MICROSCOPIC DEPTH RATIOS OF ANY TIBIAL MATRIX
CHANGE BY ZONE WERE REDUCED BY INHIBITION OF CAT KMicroscopic analysis demonstrated that treatment with SB-
553484 signiﬁcantly reduced the sum score of depth ratio of
any matrix change by 28% vs vehicle controls. The reduction
inmean scores for zones1e4 ranged from17% to 53% (Fig. 4).REPRESENTATIVE HISTOLOGICAL SECTIONS OF THE MOST
SEVERELY AFFECTED AREAS OF TIBIAS FROM VEHICLE AND
SB-553484-TREATED DOGSRepresentative histological sections of the most severely
affected area from the tibia of partialmedialmeniscectomized0.0
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Fig. 3. Microscopic tibial cartilage degeneration scores. Treatment with S
tilage degeneration scores by 21 and 16%, respectively (*P 0.05) vs veh
tibial cartilage degeneration score by zone by 21% and the zone 1 score
per groudogs treated with either vehicle or SB-553484 are shown in
Fig. 5. The approximate mean score for the vehicle treated
animal demonstrated proteoglycan loss in the anterior, mid-
dle and posterior levels extending through 15%, 60% and
30%, respectively, of the cartilage thickness (Fig. 5, top
panel). In contrast, histological sections of the most severely
affected area from the tibia of a SB-553484-treated dog with
the approximatemean score for the group demonstrated pro-
teoglycan loss in the anterior, middle and posterior levels ex-
tending through 15%, 40% and 10%, respectively, of the
cartilage thickness (Fig. 5, bottom panel).BIOMARKERS FOR COLLAGEN TYPE I AND TYPE II
DEGRADATION PRODUCTS, CTX-I AND CTX-II, WERE
REDUCED SIGNIFICANTLY BY INHIBITION OF CAT KThe urinary biomarker for bone degradation, the collagen
type I degradation product, CTX-I, was reduced signiﬁcantly
by 80% in SB-553484 vs vehicle treated controls at day 21
(Fig. 6).
The urinary biomarker for cartilage degradation, the colla-
gen type II degradation product, CTX-II, was reduced signif-
icantly by 70% in SB-553484 vs vehicle treated controls at
day 21 (Fig. 6).Surgery + SB-553484
ent Group
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B-553484 reduced signiﬁcantly the sum and middle level tibial car-
icle controls (Fig. 3a). Treatment with SB-553484 reduced the sum
signiﬁcantly by 32% (*P 0.05) vs vehicle controls (Fig. 3b). n¼ 20
p.
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Fig. 4. Microscopic tibial depth ratio any matrix change. Treatment
with SB-553484 reduced signiﬁcantly the sum tibial depth ratio any
matrix change by 28% (*P 0.05) vs vehicle controls. n¼ 20 per
group.
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Due to the lack of disease-modifying therapies for OA,
there are signiﬁcant ongoing efforts to identify molecular tar-
gets and to develop therapies that have the potential to
modify the structural aspects of OA. In this study, we tested
the inhibition of cat K on osteoarthritic lesion development in
an experimental model of OA in the beagle dog induced byFig. 5. Representative sections of the most severely affected areas of tib
affected areas from the tibia of a surgicalþ vehicle dog (top panel) with
in the anterior, middle and posterior level extending through 15%, 60% a
affected areas from the tibia of a surgicalþSB-553484-treated dog (botto
teoglycan loss in the anterior middle and posterior levels extending thro
Mag. 75partial medial meniscectomy. Our results indicate mild to
moderate beneﬁcial effects of treatment with the cat K inhib-
itor, SB-553484, on both gross and histopathological mea-
sures of cartilage lesion development. While the more
commonly used Pond-Nuki ACL transection model induces
a highly unstable joint and lesions of early cartilage hyper-
trophy and large osteophytes with variable cartilage degen-
eration over many months, the partial medial meniscectomy
model results in focal cartilage degeneration on the medial
side of the joint, in a consistent location in a relatively short
time frame. The degree of joint instability is minor so there is
less hypertrophy to complicate interpretation. Therefore the
meniscectomy model is more suitable for the evaluation of
potential effects of chondroprotection. In this relatively se-
vere, rapidly progressing model of OA, a major component
of the lesion pathogenesis is mechanically driven22. This
aspect of the model was a factor in choosing a prophylactic
strategy. Previous studies with other pharmacological
agents in this model have demonstrated maximal protection
in the range of 30e40% for various parameters22. This is
the ﬁrst report of a signiﬁcant protective effect of cat K inhi-
bition in the dog partial medial meniscectomy-induced
model of OA and the magnitude of protection is roughly
comparable to what has been reported previously in this
and other models18,22,23.
In OA, the damage and loss of the articular cartilage from
the joint surface is mediated by the degradation and loss of
the two main structural components of the cartilage matrix,
aggrecan and CTX-II24e26. For this reason, the inhibition of
aggrecan and CTX-II degradation has been the principal
target of therapeutic intervention for OA. Cat K digestsias from vehicle and SB-553484-treated dogs. The most severely
the approximate mean score for the group show proteoglycan loss
nd 30%, respectively, of the cartilage thickness. The most severely
m panel) with the approximate mean score for the group show pro-
ugh 15%, 40% and 10%, respectively, of the cartilage thickness.
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Fig. 6. Urinary biomarkers for the collagen type I and type II degra-
dation products, CTX-I and CTX-II. The urinary biomarker for bone
degradation, CTX-I, was reduced signiﬁcantly by 82% and 74% at
day 7 and 21, respectively (P¼ 0.0000) in SB-553484 vs vehicle
controls. The urinary biomarker for cartilage degradation, CTX-II,
was reduced signiﬁcantly by 67% and 72% on day 7 and 21,
respectively (P¼ 0.000) in SB-553484 vs vehicle controls.
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supporting a role for the enzyme in both bone and cartilage
turnover. Cat K also possesses the ability to cleave aggre-
can17 at multiple sites, ultimately resulting in complete hy-
drolysis of the proteoglycan at acidic pH. Additionally, the
cleavage of collagen by cat K appears to be enhanced by
the presence of glycosaminoglycans10. The demonstration
that cat K digests both CTX-II and aggrecan, the two major
structural components of articular cartilage, combined with
its already established role in bone turnover provides
a strong rationale for targeting this protease for therapeutic
intervention in OA.
Cat K has been localized to a number of osteoarthritic tis-
sues including cartilage, synovium9,11 and subchondral
bone8. In a transgenic Del 1 mouse model, a short deletion
mutation in the CTX-II transgene predisposes the animals
to early onset OA. In these animals, cat K mRNA expres-
sion was upregulated and localized primarily to the sites
of damage in the cartilage13. In articular cartilage from OA
patients, expression of cat K increased as the severity of
the disease increased12. Furthermore, this same study re-
ported a decrease in the pH at the articular cartilage sur-
faces which correlated with the severity of lesion damage.
The acidic milieu surrounding the cartilage would therefore
provide optimal conditions for cat K protease activity. The
expression of cat K has also been shown to be enhanced
in the subchondral bone in a dog model of surgically in-
duced OA8. In this study, cat K was localized in osteoclasts
in close proximity to the OA lesions. Recently, evidence for
the role of cat K in naturally occurring equine OA has been
reported27. Taken together, these data provide clear evi-
dence that cat K is expressed in the affected tissues in
OA and, importantly, the expression appears to correlate
with the degree of pathologic change.
It is apparent that OA is multifactorial in nature and not
manifested solely by changes to cartilage. The role of
bone turnover and changes to the subchondral bone inthe pathogenesis of OA has recently received increased at-
tention28. Multiple examples of the efﬁcacy of bone anti-re-
sorptive agents on OA pathology have been demonstrated.
For example, the bisphosphonates risedronate, zolendro-
nate and alendronate were effective in reducing lesion
scores in rabbit and rat models of OA29e31 and alendronate
also reduced the collagen type II degradation biomarker,
CTX-II31. Additionally, calcitonin has been shown to be ef-
fective in dog and rabbit models of OA, likely by decreasing
the enhanced turnover of subchondral bone32,33. Cat K rep-
resents the main proteolytic activity in bone resorption by
osteoclasts5,6 and inhibitors of cat K have been demon-
strated to protect against bone loss21,34 in osteoporosis.
Based on these data, the inhibition of cat K may be ex-
pected to be protective in the bone-related aspects of OA
pathology in addition to its direct role in cartilage.
Clinical development is greatly aided by the availability of
biomarkers that provide for rapid assessment of disease
progression or response to therapy. There is a great need
for both mechanistic biomarkers for OA as well as surro-
gate. This study offered us an opportunity to measure sev-
eral biochemical biomarkers. In addition to the gross and
histological indices, inhibition of cat K by SB-553484 re-
sulted in signiﬁcant reduction in the urinary biomarkers of
both CTX-I and CTX-II degradation. A decrease in the bio-
markers was also noted in both groups relative to the pre-
surgery levels. This generalized response may have been
due to the effect of handling or twice daily dosing. As ex-
pected, the urinary collagen type I degradation marker,
CTX-I, was reduced signiﬁcantly by treatment with SB-
553484 demonstrating reduction of bone turnover and sug-
gesting a functional inhibition of cat K in vivo. The degrada-
tion of CTX-II has been demonstrated to be an early
indication of damage in the OA disease process24,35 and
the detection of biomarkers of CTX-II degradation has
been reported in association with injury36 and with progres-
sion of OA37,38. The use of the CTX-II biomarker to quanti-
tate the degradation of CTX-II has been described in both
human and animal studies of arthritis. The correlation of
CTX-II levels with the severity of joint damage has also
been reported37,39,40, as well as a positive association of el-
evated baseline CTX-II levels with risk for progression of
OA of the hip41. Although the exact enzyme(s) responsible
for the generation of the CTX-II epitope has not been iden-
tiﬁed, there is some suggestion that it may be generated by
cat K. In support of this, the work of Eyre42 has demon-
strated that pycnodysostotic patients have w82% lower
levels of urinary CTX-II, compared to normal patients. Since
subjects with pycnodysostosis lack functional cat K, it is
likely that urinary CTX-II is generated by cat K cleavage
of CTX-II. Using an antibody to the unique neoepitope gen-
erated in CTX-II by cat K, an increase in cat K activity was
demonstrated recently in aged human articular cartilage
and in OA cartilage when compared to adult nondiseased
tissue43. It is interesting to note that while SB-553484 is
most potent for cat K, it does possess some activity for
cats L, S and B. Although unlikely, it is possible that the
plasma concentration of SB-553484 in this study is sufﬁ-
cient to inhibit at least some level of other cathepsin and
therefore the biological effects of SB-553484 on CTX-II
and/or on OA lesions development could be due to cats
K, L, S or B or some combination thereof. In any case,
the CTX-II levels were signiﬁcantly reduced in association
with the inhibition of lesion severity in the animals treated
with the cat K inhibitor.
In summary, signiﬁcant beneﬁcial effects of oral treatment
with SB-553484 were demonstrated on gross and
1242 J. R. Connor et al.: Cathepsin K inhibition protective in OAhistopathological parameters measured in the partial medial
meniscectomy-induced model of OA in adult female beagle
dogs. Additionally, CTX-I and CTX-II were reduced signiﬁ-
cantly in treated dogs indicating a direct effect of the com-
pound on bone and cartilage turnover. The data suggest
that the biomarkers, CTX-I and CTX-II may provide an indi-
cation of the protective effects of inhibition of bone and car-
tilage degradation. In conclusion, the prevention of cartilage
degradation by cat K inhibition may represent a valid strat-
egy for pharmaceutical intervention in OA.Conﬂict of interest
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